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rodent- and human-based in vitro REPs, we propose that 
especially REPs derived from human-based in vitro mod-
els are weighted more heavily in establishing systemic or 
human-specific TEF values to improve human health risk 
assessment.
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DLC  Dioxin-like compound
GI  Gastrointestinal






NTP  National toxicology program
OCDF  1,2,3,4,6,7,8,9-Octachlorodibenzofuran
PBMCs  Peripheral blood mononuclear cells
PCB  Polychlorinated biphenyl
PCB 126  3,3′,4,4′,5-Pentachlorobiphenyl
PCDD  Polychlorinated dibenzo-p-dioxin
PeCDD  1,2,3,7,8-Pentachlorodibenzo-p-dioxin
PCDF  Polychlorinated dibenzofuran
1-PeCDF  1,2,3,7,8-Pentachlorodibenzofuran
4-PeCDF  2,3,4,7,8-Pentachlorodibenzofuran
REP  Relative effect potencies
RfD  Reference dose
TCDD  2,3,7,8-Tetrachlorodibenzo-p-dioxin
TCDF  2,3,7,8-Tetrachlorodibenzofuran
TEF  Toxic equivalency factor
Abstract Toxic equivalency factors (TEFs) are generally 
applied for estimating human risk of dioxins and dioxin-
like compounds using systemic (e.g., blood) levels, even 
though these TEFs are established based on intake doses 
in rodent studies. This review shows that systemic rela-
tive effect potencies (REPs) can deviate substantially from 
intake REPs, but are similar to in vitro-derived REPs. Inter-
estingly, the in vitro REPs for 1,2,3,4,6,7,8-heptachlorod-
ibenzo-p-dioxin (HpCDD) and 2,3,4,7,8-pentachlorod-
ibenzofuran (4-PeCDF) are up to one order of magnitude 
higher than their in vivo REPs and WHO-TEFs, based on 
oral intake. In addition, clear species-differences in in vitro 
REPs were apparent for some congeners. Especially the 
human-derived REP for polychlorinated biphenyl 126 is 
one to two orders of magnitude lower than rodent REPs 
and its current WHO-TEF. Next, suggested adapted sys-
temic or human-specific TEFs for these congeners were 
applied to calculate changes in systemic TEQ concentra-
tions in studies from the USA, Germany and Japan and 
compared with either the JECFA TDI or USEPA RfD of 
TCDD. Overall, the effect of such TEF changes for these 
three congeners on total TEQ roughly balances each other 
out in the general population. However, results may be dif-
ferent for situations in which a specific group of congeners 
dominates. For those congeners that show a distinct devia-
tion between either intake and systemic REPs or between 
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TEQ  Toxic equivalency
TDI  Tolerable daily intake
WHO  World Health Organization
Introduction
Assessing the potential risk associated with exposure 
to dioxin-like compounds is challenging, as humans 
and wildlife are exposed to a complex mixture of these 
structurally related compounds (Safe 1994a). Based 
on the assumption that they share the same mecha-
nism of action and data from experimental studies, it 
is accepted that their individual toxicities are addi-
tive. This has led to the development of the toxic 
equivalency concept (Safe 1990, 1994b), in which 
each congener is assigned a specific toxic equiva-
lency factor (TEF) that reflects its potency to produce 
an aryl hydrocarbon receptor (AhR)-mediated bio-
logical or toxicological effect compared with the most 
potent congener, 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD). To characterize the total toxicity in a matrix, 
such as food, total toxic equivalencies (TEQs) can be 
calculated by multiplying the concentration of each 
congener with its TEF value, after which it is summed 
up to calculate total TEQs. This approach is now gen-
erally used for risk characterization in food, feed and 
human populations.
From the early 1990s, the World Health Organization 
(WHO) started organizing international expert meetings 
with the objective of harmonizing TEFs for dioxin and 
dioxin-like compounds (DLCs). In 1993, the first evalu-
ation was done that resulted in human and mammalian 
WHO-TEFs (Ahlborg et al. 1994). Since the second 
reevaluation in 1998, WHO-TEFs have been distin-
guished between mammals, birds and fish, with mamma-
lian WHO-TEFs being used for human risk assessment 
(Van den Berg et al. 1998). In June 2005, a third WHO 
expert meeting was held to reevaluate the mammalian 
1998 WHO-TEF values. For the latter meeting, a data-
base with all known in vivo and in vitro relative effect 
potencies (REPs) was compiled that formed the basis 
of the present WHO-TEFs (Van den Berg et al. 2006; 
Haws et al. 2006). Because these TEFs are derived from 
a range of REPs using various endpoints and bioassays, 
the WHO expert panels from 1998 and 2006 estimated 
that these TEFs are surrounded by at least an order of 
magnitude uncertainty (Van den Berg et al. 1998, 2006). 
Currently, there are 7 polychlorinated dibenzo-p-dioxins 
(PCDDs), 10 polychlorinated dibenzofurans (PCDFs) 
and 12 dioxin-like polychlorinated biphenyls (PCBs) that 
have been assigned with a WHO-TEF value (see Tables 1 
or 2).
Despite the large amount of supporting toxicological data 
on DLCs, some crucial gaps still exist in the present TEF 
methodology for these compounds. One major concern is 
whether the current WHO-TEFs, which are primarily based 
on in vivo studies with oral dosage, can also be used for 
human risk assessment when based on a systemic concen-
tration, e.g., blood. Several studies already showed that for 
some congeners, blood-based REPs could be significantly 
different from those based on oral (intake) doses. This sug-
gests that these “intake” REPs for hazard characterization 
might lead to misinterpretation of the risk when applied to 
blood concentrations (DeVito et al. 1997, 2000; van Ede 
et al. 2013, 2014a). Another important potential pitfall in 
the current WHO-TEFs comes from the fact that these are 
mostly based on rodent studies, but are ubiquitously applied 
for human risk assessment. Both uncertainties have been 
explicitly acknowledged during the most recent WHO-TEF 
expert meeting, and the expert panel specified the need to 
evaluate whether systemic as well as human-specific TEFs 
would result in a more accurate human risk assessment for 
DLCs (Van den Berg et al. 2006).
In this review, we address the question to what extent 
the use of current rodent-derived “intake” TEFs provides 
accurate results for human risk assessment if blood or tis-
sue levels are used. To address this issue, we firstly assess 
whether in vitro-derived REPs can be used as a surrogate 
for systemic REPs. Secondly, we calculate the impact of 
adapted TEFs, based on our evaluation, on human risk esti-
mates using existing data and reference values.
In vitro‑derived REPs as predictors for in vivo 
systemic REPs
Theoretically, it may very well be possible that results from 
in vitro studies with DLCs are a better reflection of the 
actual potency of a congener determined at the target tissue 
in in vivo studies, as in both situations, the toxicokinetic 
properties of a congener, such as absorption, distribution, 
metabolism and elimination, are not playing a major role of 
concern. In other words, in vitro-derived REPs may better 
reflect in vivo REPs based on a systemic concentration. In 
this respect, studies using primary cultures and cell lines of 
rodent but in particular human cells may provide relevant 
information that can be used for human risk assessment 
if based on systemic concentrations. To assess whether 
indeed in vitro-derived REPs are more comparable to sys-
temic REPs, we combined intake REPs and in vitro REPs 
from the 2004 REP database (Haws et al. 2006) with the 
very few in vivo studies in which intake REPs as well as 
systemic REPs were determined (Haws et al. 2006; DeVito 
et al. 2000; Van Ede et al. 2013, 2014a). These data are pre-
sented in Fig. 1.
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In Fig. 1, the comparison between the different REPs 
is shown for six congeners: 1,2,3,7,8-pentachlorodibenzo-
p-dioxin (PeCDD), 2,3,7,8-tetrachlorodibenzofuran (TCDF), 
1,2,3,7,8-pentachlorodibenzofuran (1-PeCDF), 2,3,4,7,8-pen-
tachlorodibenzofuran (4-PeCDF), 1,2,3,4,6,7,8,9-octachlo-
rodibenzofuran (OCDF) and 3,3′,4,4′,5-pentachlorobiphenyl 
(PCB 126). For each congener, two dotted lines are shown 
in the graph representing a half log uncertainty area around 
the median in vitro REP. These values are based on the sug-
gested minimal uncertainty around an established WHO-TEF 
(Van den Berg et al. 2006). However, it should be recognized 
that this ± half log uncertainty was suggested by the WHO 
panel based on expert judgment and not on actual statistical 
analysis for different congeners. Consequently, the ± half log 
uncertainty used in our review purely functions to illustrate 
deviations from the median in vitro REP and its uncertainty 
range from other types of REPs. Based on this comparison, it 
is apparent that for TCDF, 1-PeCDF, 4-PeCDF and OCDF the 
in vivo REPs are lower than the systemic REPs and in vitro 
REPs (see Fig. 1). It can be noted that for these four conge-
ners the toxicokinetics are very different compared to the ref-
erence congener TCDD. The congeners TCDF and 1-PeCDF 
are much more rapidly metabolized and eliminated than 
TCDD. In addition, due to the large molecular size, OCDF 
is more poorly absorbed from the gastrointestinal (GI) tract 
than TCDD (Birnbaum and Couture 1988; Chen et al. 2001; 
Birnbaum et al. 1980; Van Den Berg et al. 1989; Brewster 
and Birnbaum 1988). Finally, 4-PeCDF is sequestered in the 
liver to a much higher degree than TCDD due to its high affin-
ity binding to the CYP1A2 protein (Brewster and Birnbaum 
1987; Chen et al. 2001; Devito et al. 1998). As a consequence, 
systemic REPs for these congeners based on a skin or plasma 
concentration are found to be higher when compared to the 
intake REPs (Fig. 1b–e) (DeVito et al. 1997; Van Ede et al. 
2013, 2014a). For these congeners, it is clear that the systemic 
REPs are closer to the in vitro REPs than to the intake REPs. 
Such similarities are less distinct for PeCDD and PCB 126 
(Fig. 1a, f, respectively). For PCB 126, the median systemic 
REP is somewhat lower than the median in vitro REP. How-
ever, it should be noted that also the intake REPs from these 
studies were lower than the WHO-TEF and those reported in 
the 2004 REP database (see Fig. 1f). Together, these results 
suggest that in vitro REPs can potentially be a good repre-
sentative for systemic REPs, which may allow us to use the 
large amount of available in vitro data on DLCs to evaluate 










































































































































































































































































Fig. 1  Boxplot comparison of in vivo REPs based on an adminis-
tered dose (intake) or systemic concentration (blood plasma or skin) 
and in vitro-derived REPs for PeCDD (a), TCDF (b), 1-PeCDF (c), 
4-PeCDF (d), OCDF (e) and PCB 126 (f). The boxplots; in vivo—
intake—Haws et al. and in vitro—rodent—Haws et al. represent 
data from the 2004 REP database (Haws et al. 2006). The boxplots; 
in vivo—intake—this review and in vivo—systemic—this review rep-
resent data from one to four different studies in which the potency of 
the congener is determined based on either the administered (intake) 
dose or a systemic (plasma or skin) concentration (DeVito et al. 
1997, 2000; Van Ede et al. 2013, 2014a). The number above the box-
plot represents the number of REPs. The gray dotted lines represent 
the ± half log uncertainty area around the median in vitro REP
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The role of toxicokinetics and species‑differences 
in REPs
As described earlier, each step in toxicokinetics gener-
ally affects the in vivo REP of a congener, if it behaves 
significantly differently from TCDD. Moreover, species-
specific differences in toxicokinetics and toxicodynam-
ics of DLCs can also influence the REP of a congener. 
Some species-differences in AhR-mediated responses 
can clearly be attributed to genetic differences. Gener-
ally, the human AhR is considered to be relatively less 
responsive to DLCs than the rodent AhR (Ema et al. 
1994; Connor and Aylward 2006). However, if the dif-
ference in potency between species is similar for TCDD 
and a specific congener, this obviously does not lead to 
species-differences in relative effect potency. None-
theless, distinct species-specific differences in REPs 
have been described for some PCDDs and PCDFs, 
such as 4-PeCDF, 1,2,3,4,7,8-hexachlorodibenzo-
furan (4-HxCDF), 1,2,3,6,7,8-hexachlorodibenzofuran 
(6-HxCDF), 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin 
(HpCDD) and 1,2,3,4,7,8,9-heptachlorodibenzofuran 
(9-HpCDF) (Sutter et al. 2010; Nagayama et al. 1985; 
Van Ede et al. 2014b; Larsson et al. 2015), but particu-
larly the species-difference in toxicity of the non-ortho-
substituted PCB 126 has been subject of much scientific 
debate (Nagayama et al. 1985; Silkworth et al. 2005; 
Sutter et al. 2010; Zeiger et al. 2001; Van Duursen et al. 
2003, 2005; Van Ede et al. 2014b; Larsson et al. 2015).
In order to evaluate congener- and species-specific dif-
ferences in various REPs between humans and rodents, 
we combined REP data that were published since 2005 
with the REPs from the 2004 database (Haws et al. 2006) 
for HpCDD, 4-PeCDF and PCB 126. These congeners 
were chosen based on their suspected deviation from their 
current WHO-TEFs and their quantitative contribution to 
the total amount of TEQs in human blood (see Table 1).
HpCDD
For HpCDD, the 2004 REP database contains 12 in vivo 
REPs and 5 in vitro REPs (Haws et al. 2006). The 12 
in vivo REPs were all obtained from rat studies and show 
a median REP of 0.01, which equals the WHO-TEF. The 
median rodent-based in vitro REP for HpCDD is with 0.03 
slightly higher than the median in vivo REP of 0.01 (see 
Fig. 2a). The 2004 REP database contains only 1 human 
in vitro REP for HpCDD, which is 0.04 and similar to the 
median rodent in vitro REP (see Fig. 2a).
Since 2005, two new studies with human and rodent 
in vitro experiments have been published for this con-
gener providing, respectively, 8 and 10 new REPs (Van 
Ede et al. 2014b; Larsson et al. 2015). Together with the 
2004 REP database, the median rodent and human in vitro 
REPs are 0.05 and 0.15, respectively, which indicates a 
possible higher affinity of HpCDD for the human AhR 
compared with that of rodents. However, there is a broad 
overlap between the confidence intervals of the rodent 
and human in vitro REPs (see Fig. 2b). If the information 
from Fig. 2a, b is combined, two conclusions for HpCDD 
can be drawn. Rodent in vivo REPs are on average lower 
than those obtained from in vitro rodent models, which 
may be explained by lower bioavailability from the GI 
tract and higher sequestration for this congener compared 
to TCDD. The median REP of HpCDD in human in vitro 
models appears a factor three higher than those obtained 
from comparable rodent in vitro systems, suggesting that 
HpCDD may be more potent in humans once it is circulat-
ing in the body. However, in view of the uncertainties sur-
rounding these HpCDD REPs, such a conclusion should 
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Fig. 2  Boxplot comparison of in vivo- and in vitro-derived REPs 
for HpCDD based on rodent or human data from 2004 REP database 
(Haws et al. 2006) alone (a) and in combination with newly published 
literature (b). Numbers indicate the number of REPs. The black 
dashed line and gray area represent the current WHO-TEF value of 
0.01 for HpCDD ± half log uncertainty
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be considered preliminary and must be substantiated 
further.
4‑PeCDF
For 4-PeCDF, the 2004 REP database contains 80 in vivo 
and 17 in vitro REPs obtained from 20 and 10 studies, 
respectively (Haws et al. 2006). The in vivo REPs comprise 
21 mouse- and 57 rat-based REPs, the latter mainly con-
sisting of in vivo studies from the National Toxicology Pro-
gram (NTP) using female Sprague–Dawley rats (National 
Toxicology Program 2006b). The median rodent in vivo 
REP for 4-PeCDF is 0.2, closely similar to the WHO-TEF 
of 0.3. In contrast, the median rodent in vitro REP, consist-
ing of 2 mouse and 10 rat REPs, is 0.7, which is higher 
than the WHO-TEF and the median rodent in vivo REP 
(see Fig. 3a). The 5 human in vitro REPs from the 2004 
REP database were obtained from 2 studies and show a 
median REP of 1, which is similar to the rodent median 
in vitro REP and clearly higher than that of the WHO-TEF.
Since 2005, three human in vitro studies published 
REPs for 4-PeCDF using primary peripheral blood mon-
onuclear cells (PBMCs), hepatocytes, keratinocytes and 
human hepatoblastoma (HepG2) cells (Budinsky et al. 
2010; Van Ede et al. 2014b; Larsson et al. 2015). Com-
bining these new REPs with the existing 2004 database 
REPs does not change the median REP of 1 for the human 
in vitro data (see Fig. 3b). As the human in vitro REPs are 
in line with the rodent-derived in vitro REPs for 4-PeCDF, 
no obvious toxicodynamic differences for AhR-mediated 
activities between rodents and humans are present for 
4-PeCDF and suggest that for 4-PeCDF there are no spe-
cies-specific differences. However, a difference between 
in vivo and in vitro REPs, which is likely due to the higher 
liver sequestration of 4-PeCDF compared to TCDD, seems 
apparent.
Pcb 126
For PCB 126, the WHO-TEF of 0.1 corresponds with the 
median of 86 in vivo and 29 in vitro REPs obtained from 
20 and 19 studies, respectively (Haws et al. 2006). These 
in vivo REPs comprise of 23 mouse- and 63 rat-based 
REPs, the latter predominantly consisting of in vivo studies 
from the NTP using female Sprague–Dawley rats (National 
Toxicology Program 2006a). REPs for PCB 126 from rat 
studies are consistently close to 0.1 (Haws et al. 2006). A 
wider distribution exists for the mouse-based in vivo REPs 
in this database. The median rodent in vitro REP for PCB 
126 is with 0.09 very similar to the median in vivo REP of 
0.1.
Of the 29 in vitro REPs for PCB 126 within this 2004 
REP database, 8 are derived from studies using human cells 
(Drenth et al. 1998; Zeiger et al. 2001; Van Duursen et al. 
2003; Pang et al. 1999). Compared with the rodent data, the 
human in vitro REPs are clearly much lower with a median 
REP of 0.009 (range 0.0007–0.02) (see Fig. 4). Since 2005, 
another seven in vitro studies with human primary PBMCs, 
hepatocytes, keratinocytes or HepG2 cells were conducted 
that determined the relative potency of PCB 126. These 
studies show REPs ranging from 0.00009 to 0.06 (Van 
Duursen et al. 2005; Silkworth et al. 2005; Sutter et al. 
2010; Westerink et al. 2008; Carlson et al. 2009; Larsson 
et al. 2015; Van Ede et al. 2014b). When we combine the 
newly published data with those from the 2004 REP data-
base, it is evident that in vitro REPs from different human 
cell systems are consistently one to two orders of magnitude 
lower than the current WHO-TEF. These data unmistakably 
show a species-difference in AhR-mediated effects between 
humans and rodents for PCB 126. As a result, we may 
consistently be overestimating the toxicity of PCB 126 for 
humans when using rodent data or the present WHO-TEF.
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Fig. 3  Boxplot comparison of in vivo- and in vitro-derived REPs for 
4-PeCDF based on rodent or human data from 2004 REP database 
(Haws et al. 2006) alone (a) and in combination with newly published 
human REPs (b). Numbers indicate the number of REPs. The black 
dashed line and gray area represent the current WHO-TEF value of 
0.3 for 4-PeCDF ± half log uncertainty
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Human risk assessment of DLCs in perspective
In order to put the above observations into perspective for 
human risk assessment, we selected three different studies 
in which the background blood, plasma or adipose tissue 
concentrations of DLCs and total TEQs were measured 
(see Table 1) (Watanabe et al. 2013; Wittsiepe et al. 2007; 
Rawn et al. 2012). The study of Rawn et al. represents a 
national baseline estimate of concentrations of DLCs in 
Canadians (Rawn et al. 2012). The study of Wittsiepe et al. 
represents the concentrations of DLCs in German moth-
ers living in an industrialized area of Germany (Wittsiepe 
et al. 2007), while the study of Watanabe et al. represents 
the concentrations of DLCs in randomly selected deceased 
patients in Japan (Watanabe et al. 2013).
Dioxins
It is of interest to note that after PeCDD, 1,2,3,6,7,8-hex-
achlorodibenzo-p-dioxin (6-HxCDD) is the second most 
important contributor to the total amount of TEQs in the 
general population based on the current WHO-TEFs (see 
Table 1), accounting for approximately 20, 8 and 10 % 
of the TEQ in the Canadian, German and Japanese back-
ground levels (Wittsiepe et al. 2007; Watanabe et al. 2013; 
Rawn et al. 2012). In comparison, the quantitative contri-
bution of HpCDD is approximately 0.2–2 % of the total 
amount of TEQs using the current WHO-TEFs. However, if 
we look at the results of our evaluation, the median rodent 
and human in vitro REP for HpCDD is 0.1, and our data 
indicate that such a value would be more appropriate for 
a systemic REP. Such a higher value for HpCDD signifi-
cantly increases its contribution to the total TEQ meas-
ured in blood or adipose tissue in the different popula-
tions. As a result, HpCDD would become one of the major 
contributors to the total amount of TEQs in the blood (for 
comparisons, see Table 1) (Wittsiepe et al. 2007; Watanabe 
et al. 2013; Rawn et al. 2012). It should also be noted that 
for the other dioxins with WHO-TEF values, the 2004 REP 
database does not show a clear deviation between in vitro 
and in vivo or human and rodent data. For the human risk 
assessment of dioxins based on blood levels, it would mean 
that only a separate systemic TEF for HpCDD is recom-
mended (for comparison, see Table 2) (Haws et al. 2006).
Furans
Of the furans, in particular 4-PeCDF is a substantial con-
tributor to the total TEQs in the human population. Our 
review shows that the median systemic REP as well as 
rodent and human in vitro REPs is higher than the rodent 
median in vivo REP and the present WHO-TEF. However, 
the deviation found is mostly within the half log uncer-
tainty around the WHO-TEF of 0.3 (see Figs. 1, 3). Never-
theless, it should be noted that the 75th percentile of the 
systemic REP distribution and the 25th to 75th percentile 
REP distribution for rodent and human in vitro REPs are 
above the current WHO-TEF for 4-PeCDF.1 If a systemic 
TEF of 1 for 4-PeCDF is applied for the systemic blood 
and adipose concentrations in the different populations, this 
would result in an even stronger contribution of this conge-
ner to the total amount of TEQs (for comparison, see 
Table 1) (Wittsiepe et al. 2007; Watanabe et al. 2013; Rawn 
et al. 2012).
For TCDF, 1-PeCDF, 4-HxCDF, 6-HxCDF, 9-HpCDF and 
OCDF, differences between in vitro and in vivo or between 
human and rodent REPs were also observed (see Table 2). 
1 The 75th percentile was used during the 2006 expert meeting as a 
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Fig. 4  Boxplot comparison of in vivo and in vitro-derived REPs for 
PCB 126 based on rodent or human data from 2004 REP database 
(Haws et al. 2006) alone (a) and in combination with newly published 
human REPs (b). Numbers indicate the number of REPs. The black 
dashed line and gray area represent the current WHO-TEF value of 
0.1 for PCB 126 ± half log uncertainty
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However, the quantitative contributions of these congeners, 
except for 4-HxCDF and 6-HxCDF, are very low in blood and 
will have little impact on total TEQs in the general popula-
tion (see Table 1) (Wittsiepe et al. 2007; Watanabe et al. 2013; 
Rawn et al. 2012). For 4-HxCDF higher human and rodent 
in vitro REPs with a median of, respectively, 1.5 and 0.3 were 
seen compared to the median in vivo REP of 0.05 or WHO-
TEF of 0.1 (Larsson et al. 2015; Haws et al. 2006, Van Ede 
et al. 2014b). In addition, a higher human in vitro REP of 1 for 
6-HxCDF was determined in human keratinocytes compared 
to the in vitro and in vivo rodent REPs as well as the WHO-
TEF of 0.1 (Sutter et al. 2010). Applying a higher systemic or 
human-specific TEF value for these two congeners has signifi-
cant implications, as the contribution to the total TEQs based 
on their current WHO-TEFs is already above 1 % (see Table 1) 
(Wittsiepe et al. 2007; Watanabe et al. 2013; Rawn et al. 2012).
PCBs
For PCB 126, the combined human REP data from the 
literature, shown in Fig. 4, gives a median human REP of 
0.003. This is almost a 100 times lower than the WHO-TEF 
of 0.1, and far outside its suggested ± half log uncertainty 
range. PCB 126 is one of the major contributors to the total 
amount of TEQs in human blood when using the present 
WHO-TEFs. If the TEF for PCB 126 would be adjusted for 
humans from 0.1 to 0.003, the contribution of PCB 126 to 
the total TEQ goes from 15–35 to 1–2 % and becomes neg-
ligible (see Table 1) (Wittsiepe et al. 2007; Watanabe et al. 
2013; Rawn et al. 2012).
In contrast to dioxins and furans, multiple experimental 
studies indicate that humans may be less responsive to PCB 
congeners that are (relatively) potent AhR agonists in rodents. 
As can be seen from Fig. 4b, this is clearly the case for the 
non-ortho-substituted PCB 126, but it also applies for others 
such as PCB 169 and mono-ortho-PCBs. Especially the lat-
ter group of PCB congeners has been shown a lack of capa-
bility to induce a significant dioxin-like response in human 
primary cells or cell lines (see Table 2) (Zeiger et al. 2001; 
Endo et al. 2003; Larsson et al. 2015; Van Ede et al. 2014b). 
The clear difference in response between these PCBs versus 
PCDDs and PCDFs in human systems compared with those 
of rodents most likely originates from species-specific bind-
ing properties to the AhR, which specifically makes humans 
less sensitive to PCBs (Petkov et al. 2010).
Effect on total TEQ
Our review of the more recent scientific data indicates that 
it may be appropriate to use human-specific or systemic 
TEFs instead of intake WHO-TEFs for human risk assess-
ment for 6-HpCDD, 4-PeCDF and PCB 126, when based 
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Table 2  Summary evaluation of WHO-TEF congeners for in vitro versus in vivo and human vs. rodent differences, and proposed human sys-
temic TEF (SYS-TEF) values, if different from WHO-TEF
Congener WHO-TEFa Evidence for Differences


















 2378-TCDF 0.1 Yes 3, 5 No proposed SYS-
TEF as mean REP is 
similar to WHO-
TEF (see Fig. 1)
 12378-PeCDF 0.03 Yes 0.1 3, 5 See Fig. 1
 23478-PeCDF 0.3 Yes 1 1, 3, 5, 6, 10, 11, 12 See Fig. 3
 123478-HxCDF 0.1 Yes Possibly 1 5, 6, 12




 1234789-HpCDF 0.01 Yes 0.3 5, 6, 12
 OCDF 0.0003 Yes 0.001 3, 5 See Fig. 1
Non-ortho-substi-
tuted PCBs
 PCB 77 0.0001 Possibly 4, 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 81 0.0003 Possibly 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 126 0.1 Yes 0.03 2, 5, 6, 7, 8, 9, 12, 13 See Fig. 4
 PCB 169 0.03 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
Mono-ortho-substi-
tuted PCBs
 PCB 105 0.00003 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 114 0.00003 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
1303Arch Toxicol (2016) 90:1293–1305 
1 3
some suggestions for TEF changes are given for these con-
geners. If such a change would be adapted, it would change 
the total amount of TEQs in human blood. Such a change 
would result in an increase in the relative contribution to the 
total TEQs by PCDDs and PCDFs of 5–23 and 62–66 %, 
respectively, and a 75–77 % decrease in contribution of total 
TEQs by non-ortho-PCBs (Table 1) (Wittsiepe et al. 2007; 
Rawn et al. 2012; Watanabe et al. 2013). Overall, the effect 
of such TEF changes for these three congeners on total TEQ 
would roughly balance each other out in the general popula-
tion. However, results may be different for those situations 
in which a specific group of congeners dominates, e.g, a 
food contamination incident or under conditions of unusual 
occupational exposures. Furthermore, also the effects of for 
instance 4-HxCDF or 6-HxCDF are not taken into account.
The above systemic TEQ estimates that were calculated 
using the adjusted systemic TEF values can be further eval-
uated in a risk assessment context. Previously, Biomonitor-
ing Equivalents (BEs), which are estimates of steady-state 
biomarker concentrations consistent with chronic exposure 
at a reference dose (RfD) or tolerable daily intake (TDI), 
have been estimated for TCDD (Aylward et al. 2008, 
2013). The physiologically based pharmacokinetic (PBPK) 
model for TCDD selected by USEPA in their 2012 RfD 
evaluation was used to estimate steady-state serum TCDD 
concentrations consistent with chronic exposure at the 
USEPA reference dose (RfD) or the WHO JECFA TDI. 
The USEPA chronic RfD for TCDD is 0.7 pg TEQ/kg-d. 
The corresponding BERfD values for serum concentrations 
from chronic exposure at this rate are approximately 15 pg 
TEQ/g lipid for adolescents, rising to approximately 21 pg 
TEQ/g lipid for adults. Calculated systemic TEQ concen-
trations can be compared directly to the BE values to evalu-
ate whether the chronic population exposure is well below, 
near or above the exposure guidance values. The calculated 
systemic TEQ values, using the adjusted systemic TEF 
values, for the average population presented in Table 1 are 
near (Rawn et al. 2012) or above the BERfD (Wittsiepe et al. 
2007; Watanabe et al. 2013). The JECFA TDI is approxi-
mately 2.3 pg TEQ/kg-d, leading to a BETDI of approxi-
mately 40–70 pg TEQ/g lipid, depending on assumptions 
regarding body composition. All three populations mean 
values fall within or below this range.
Conclusions and recommendations
Selection of TEF values for dioxin-like compounds that are 
most appropriate and accurate for their intended applications 
is important for human risk assessment. For the WHO-TEF 
a  Current WHO-TEF (Van den Berg et al. 2006)
b  1 Budinsky et al. (2010), 2 Carlson et al. (2009), 3 DeVito et al. (1997), 4 Endo et al. (2003), 5 Haws et al. (2006), 6 Larsson et al. (2015), 
7 Silkworth et al. (2005), 8 Sutter et al. (2010), 9 Van Duursen et al. (2005), 10 Van Ede et al. (2013), 11 Van Ede et al. (2014a), 12 Van Ede et al. 
(2014b), 13 Westerink et al. (2008), 14 Zeiger et al. (2001)
Table 2  continued
Congener WHO-TEFa Evidence for Differences







 PCB 118 0.00003 Possibly 4, 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 156 0.00003 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 157 0.00003 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 167 0.00003 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
 PCB 189 0.00003 Possibly 6, 12, 14 No CYP1A1 induc-
tion at all or high 
enough to calculate 
REP in human cells
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methodology, rodent studies based on an administered dose 
have been considered most suitable for human risk assess-
ment. However, human exposure to DLCs is often reported 
based on blood or tissue levels. In this review, we have 
addressed the question to which extent the present intake-
based WHO-TEFs are also useful for studies reporting sys-
temic concentration of DLCs, e.g., in blood. It can be pro-
posed that the use of systemic REPs with results from human 
in vitro studies may provide a more accurate human risk 
assessment, because it will bridge the gap in toxicokinetics 
and toxicodynamics between species. Our review shows that 
in vitro REPs of some congeners may well represent sys-
temic REPs. Thus, in vitro REPs may provide a reasonable 
basis for assessing systemic as well as human-specific REPs. 
Based on the existing data that have been used in this review, 
a number of specific conclusions can be drawn:
•	 Both rodent and human in vitro REPs for 6-HpCDD are 
up to one order of magnitude higher than their current 
WHO-TEFs, with human in vitro data tending to have 
a higher relative potency than the rodent in vitro data 
(Fig. 2).
•	 Rodent and human in vitro REPs for 4-PeCDF span a 
similar range and indicate that this congener is more 
potent on a systemic basis than on an intake basis, per-
haps by as much as one order of magnitude (Fig. 3).
•	 Combining REPs from the 2004 REP database with 
newly published data demonstrates that the human-based 
in vitro REP for PCB 126 is at least one, but possibly up 
to two orders of magnitude lower than expected based on 
the current WHO-TEF (Fig. 4).
For those congeners that show a distinct deviation 
between either intake and systemic REPs or between 
rodent- and human-based in vitro REPs, we propose that 
in vitro REP data are weighted more heavily in establish-
ing systemic or human-specific TEF values. Especially 
REPs derived from human-based in vitro models should be 
considered more valuable contributors to improve human 
health risk assessment for dioxin-like compounds.
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